$0.99
+0.04 (+4.73%)
Open$0.94
Previous Close$0.94
Day High$1.04
Day Low$0.94
52W High$12.85
52W Low$5.01
Volume—
Avg Volume255.6K
Market Cap42.15M
P/E Ratio24.41
EPS$0.39
SectorBiotechnology
Analyst Ratings
Strong Buy
8 analysts
Price Target
+1,021.5% upside
Current
$0.99
$0.99
Target
$11.07
$11.07
$6.75
$11.07 avg
$12.78
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 8.11M | 7.77M | 7.02M |
| Net Income | 1.93M | 1.80M | 1.31M |
| Profit Margin | 23.8% | 23.2% | 18.7% |
| EBITDA | 2.47M | 2.38M | 2.09M |
| Free Cash Flow | 1.90M | 1.78M | 1.31M |
| Rev Growth | +5.9% | +3.8% | -2.2% |
| Debt/Equity | 0.71 | 0.84 | 0.79 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |